Share information
276.50 €
-0.58 %
03/11/2026 17:35
-0.58 %
Open
High
Low
Volume
280.00 €
281.50 €
275.70 €
206,880
Latest News
22-Oct-2026
Strong Performance Drives Further Upgrade to UCB’s 2026 Financial Guidance
19-Oct-2026
Transparency notification Wellington
16-Oct-2026
UCB announces U.S. FDA approval for ZILBRYSQ[®] (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis
30-Sep-2026
UCB announces new data at EADV 2026 supporting earlier use of BIMZELX[®] (bimekizumab) for treating hidradenitis suppurativa